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Changes in gene expression (GE) during antidepressant treatment may increase 
understanding of the action of antidepressant medications and serve as biomarkers of 
efficacy. GE changes in peripheral blood are desirable because they can be assessed 
easily on multiple occasions during treatment. We report here on GE changes in 68 
individuals who were treated for 8 weeks with either escitalopram alone, or escitalopram 
followed by bupropion. GE changes were assessed after 1, 2, and 8 weeks of treatment, 
with significant changes observed in 156, 121, and 585 peripheral blood gene transcripts, 
respectively. Thirty-one transcript changes were shared between the 1- and 8-week 
time points (seven upregulated, 24 downregulated). Differences were detected between 
the escitalopram- and bupropion-treated subjects, although there was no significant 
association between GE changes and clinical outcome. A subset of 18 genes overlapped 
with those previously identified as differentially expressed in subjects with MDD compared 
with healthy control subjects. There was statistically significant overlap between genes 
differentially expressed in the current and previous studies, with 10 genes overlapping 
in at least two previous studies. There was no enrichment for genes overexpressed in 
nervous system cell types, but there was a trend toward enrichment for genes in the 
WNT/β-catenin pathway in the anterior thalamus; three genes in this pathway showed 
differential expression in the present and in three previous studies. Our dataset and other 
similar studies will provide an important source of information about potential biomarkers 
of recovery and for potential dysregulation of GE in MDD.
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INTRODUCTION
The mechanism of action (MOA) of antidepressant medications 
remains incompletely understood. Antidepressant medications 
are remarkably pleiotropic in their effects. In addition to binding 
to serotonin and/or norepinephrine transporters (SERT and 
NET, respectively), their affinity for other neurotransmitter 
receptors and ligand-gated ion channels may be relevant to 
their effects (Bianchi and Botzolakis, 2010). In addition, the 
acute effect on aminergic signaling has the potential to influence 
a wide range of downstream genetic pathways implicated in 
neurogenesis, synaptic plasticity, neuronal excitability, and 
metabolism (Baudry et al., 2011). To date, the identity of genes 
that are consistently up- or down-regulated by antidepressants 
remains obscure. The application of genomic techniques to 
patients undergoing treatment with antidepressants has the 
potential to identify clusters of genes and/or pathways that 
undergo transcriptional regulation in response to these drugs. 
Identification of reproducible gene expression (GE) changes 
during antidepressant treatment will be the first step toward the 
long-term goal of elucidating which changes are required for the 
relief of depressive symptoms (Bartova et al., 2010; Baudry et al., 
2011; Redei et al., 2014).
Because of the limited accessibility of neuronal tissue, studies 
of the transcriptome in patients undergoing treatment for MDD 
have focused upon GE changes in peripheral blood (Tylee et al., 
2013). Studies often have been of limited size but have examined 
changes during treatment with a variety of medications (Belzeaux 
et al., 2010; Mullins et al., 2014; Watanabe et al., 2015; Miyata 
et al., 2016) or cognitive behavioral therapy (Redei et al., 2014). 
To our knowledge, no previous study has systematically examined 
the changes in peripheral blood GE at multiple time points in 
an 8-week course of antidepressant treatment. We report here 
a study of the transcriptional changes that occur in response 
to treatment with escitalopram or bupropion in a cohort of 68 
subjects at 1, 2, and 8 weeks of medication treatment, and the 
association of these changes with clinical outcome.
METHODS
Subjects
Samples were collected from a subset of the adult subjects (age 
21–75) who participated in a double-blind controlled trial 
conducted to evaluate a neurophysiologic biomarker for use in 
assigning antidepressant medication treatment (NCT00917059 
“Personalized Response Indicators of SSRI Effectiveness in Major 
Depression” [PRISE-MD]). The objective of the overall trial was 
to assess outcomes when subjects were prospectively assigned 
to antidepressant treatment based upon biomarker status, using 
a quantitative electroencephalographic (qEEG) biomarker 
that previously had been shown to be predictive of response 
and remission during treatment with escitalopram (ESC) and 
bupropion (BUP) (Leuchter et al., 2009a; Leuchter et al., 2009b; 
Cook et al., 2013). All subjects started with 1 week of single-
blind ESC (10 mg each morning) for measuring the biomarker 
and then were randomized to continue on ESC or switch to 
BUP (150 mg each morning) under double-blind conditions for 
the remainder of the protocol. Randomization was performed 
using a biomarker-based stratification to ensure that biomarker-
positive and biomarker-negative subjects received balanced 
allocation to the treatments. The study tested the hypothesis 
that treatment concordant with the biomarker would lead to 
better outcomes than biomarker-discordant assignment. ESC 
outcomes were assessed after 7 weeks of continuous treatment 
(study week 7) while BUP outcomes were assessed after 7 weeks 
of continuous BUP (study week 8). The study was statistically 
powered to detect a difference for subjects assigned to ESC but 
not for those receiving BUP. In accordance with principles of the 
Helsinki Declaration, all protocols were approved by the UCLA 
Institutional Review Board, and all subjects provided written 
informed consent.
All subjects were diagnosed with MDD based upon structured 
interview data (Mini-International Neuropsychiatric Interview, 
or MINI) (Sheehan et al., 1998) and had a symptom severity 
score of 12 or greater on the Quick Inventory of Depressive 
Symptomatology—Self Rated version (QIDS-SR16) (Rush et al., 
2003). Subjects were excluded for serious medical or psychiatric 
comorbidities, recent exposure to electroconvulsive therapy, and 
other factors that would either pose safety concerns or render 
data uninterpretable (detailed at clinicaltrials.gov). Subjects 
were evaluated in an outpatient setting every week for evidence 
of symptomatic changes and/or side effects. The primary 
outcome measure was the score on the 17-item Hamilton 
Depression Rating Scale (Ham-D17) (Hamilton, 1960). Degree of 
improvement was defined as the change in the Ham-D17 score 
from pretreatment baseline to endpoint, with response defined 
as a decrease in Ham-D17 of ≥50% and remission as a final Ham-
D17 of ≤7.
A total of 274 adults were screened, 180 were enrolled and 
randomized, and 133 completed at least 4 weeks of the trial and 
had evaluable clinical data, with usable samples for genomic 
assays collected from a subset of 68 individuals (40 ESC, 28 BUP) 
at up to four time points during the trial: pre-treatment baseline 
and 1, 2, and 8 weeks of treatment in the protocol (see Table 1 for 
a breakdown of samples by treatment and time point).
RNA Extraction and Measurement of Gene 
Expression 
Whole blood was collected using PAXgene Blood RNA tubes 
(PreAnalytiX GmbH, Hombrechtikon, Switzerland) and 
frozen until time of extraction. Samples were extracted in one 
batch using a PAXgene Blood RNA Kit (Qiagen, Valencia CA); 
quantity and quality of RNA samples were checked using an 
TABLE 1 | Number of samples by time point and medication.
Escitalopram (ESC) Bupropion (BUP) Total
Baseline 40 24 64
Week 1 34 23 57
Week 2 35 26 61
Week 8 36 28 64
Total 145 101 246
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Agilent Bioanalyzer 2100 (Agilent, Santa Clara CA) in the UCSF 
Genome Core Facility. Total mRNA was amplified and labeled 
using the Illumina TotalPrep RNA Amplification Kit before being 
hybridized to the Illumina Expression RefSeq HT-12 BeadChip, 
querying the expression of ~47,000 RefSeq transcripts, as per 
manufacturer’s protocol. The BeadChips were then scanned with 
the Illumina iScan system and signal was extracted using the 
Illumina BeadStudio Software (Illumina, San Diego, CA).
Illumina expression assays were run on blood samples meeting 
standard QC criteria. After assay, raw data were inspected to 
remove samples with missing data for the majority of probes. 
Data were inspected after log2 transformation to screen for 
outliers, using visual inspection of correlations among samples 
and probes and calculating z-scores to find samples with low 
correlations with the rest of the dataset. A total of 14 samples 
were excluded based on QC of raw data, and the resulting 246 
samples were carried forward for analysis.
Raw GE data were preprocessed using Bioconductor packages 
for R following protocols developed by the UCLA Informatics 
Center for Neurogenetics and Neurogenomics (ICNN). 
Expression data were log2 transformed and quantile normalized; 
no batch correction was necessary as all samples were processed 
at the same time. As multiple probes may tag the same gene on the 
array, the collapseRows function was used to select a single probe 
per gene, using the absolute maximum mean expression values of 
the multiple probes. Quality-control analysis was performed by 
examining the inter-array Pearson correlations, clustering based 
on variance, and the mean absolute deviation (MAD) using the 
top 1,000 most variant probes. Twelve outliers were identified 
based on GE data and removed from further analyses. After 
quality control steps were applied, 28,105 gene transcripts were 
present in 246 samples from 68 unique subjects.
Data Analysis
Analyses of demographic and clinical outcome data were 
performed using SPSS (SPSS, Inc.; Chicago, IL). Outcome and 
demographic differences were compared between outcome groups 
using Student’s T-test. Analysis of differential GE was performed 
using a linear model fitting (LIMMA package), accounting for 
within-subject variance. Age, sex, and RNA integrity number 
(RIN) were included as covariates in all analyses. After linear 
model fitting, a Bayesian estimate of differential expression was 
calculated applying a nominal p-value threshold of 0.005. The 
resulting gene lists were interrogated using the data-driven tools 
described below.
Gene Ontology and Gene Pathways
We used the anRichment function within the WGCNA package 
in R (Langfelder and Horvath, 2008; Miller et al., 2011) to test 
for enrichment of: (1) gene ontology (GO) biological process 
terms and (2) pathway-based categories (e.g., NCBI BioSystems 
Reactome pathways). Enrichment analyses are conducted using 
a hypergeometric test, which can be used to identify whether 
a sub-population (e.g., differentially expressed genes) is over-
represented in a given sample (e.g., genes annotated with a 
specific function), when drawing from the larger population of 
probes. This test is based on a discrete probability distribution, 
representing the likelihood of obtaining a number of successful 
draws, out of N possible draws, without replacement from a 
finite population. To adjust for multiple comparisons, we applied 
a local false discovery rate (FDR) correction and report q-value 
estimates using the R q-value package for all enrichment tests.
Cell Type–Specific Enrichment Analyses
We queried data available in the RNA-seq database (Zhang et al., 
2014) to identify gene sets preferentially enriched in cell types 
highly represented in the nervous system, including astrocytes, 
endothelial cells, microglia, neurons, and oligodendrocytes 
(further subdivided by precursors, newly formed, and myelinated 
oligodendrocytes). Following the authors’ recommendations, the 
top 500 enriched genes (using FPKM > 20) were selected for 
each cell type. Because of evidence that the anterior thalamus 
may constitute a site for antidepressant medication action, we 
tested for enrichment of genes preferentially expressed in the 
thalamic structures (Hawrylycz et al., 2012), as well as genes 
involved in the Wnt/β-catenin pathway in the anterior thalamus 
(Wisniewska et al., 2012).
Reference Gene Sets From Relevant 
Published Studies
After a comprehensive review of the literature, published studies 
relevant to the current data set were compiled. This includes 
studies focusing on GE differences in MDD patients vs. controls, 
or within MDD patients as a function of treatment (Mamdani 
et al., 2011; Belzeaux et al., 2012; Menke et al., 2012; Liu et al., 
2014; Mamdani et  al., 2014; Guilloux et al., 2015; Hennings et 
al., 2015; Hodgson et al., 2016; Jansen et al., 2016). This includes 
studies of peripheral blood GE changes in humans undergoing 
treatment with citalopram and psychotherapy (n = 34) (Guilloux 
et al., 2015), citalopram alone (n = 77) (Mamdani et al., 2014), a 
variety of different psychotropic agents as well as ECT (n = 16) 
(Belzeaux et al., 2012), nortriptyline or ESC (n = 136) (Hodgson 
et al., 2016), or citalopram (n = 34) (Belzeaux et al., 2016). We 
examined genes sets differentially expressed in these previous 
studies to determine whether there was significant overlap with 
the present study, as well as to determine whether individual genes 
were reported in more than one previous study of antidepressant 
treatment, as well as the Wnt/β-catenin pathway.
Drug-Induced Gene Changes in Mice
Using the Genomic Signature Identification tool in the 
genes2mind database, we extracted lists of genes that represent 
drug-specific genomic signatures in the mouse brain following 
antidepressant administration. Specifically, we extracted the 
top 100 genes associated with BUP or fluoxetine at 1, 2, 4, and 8 
hours and all time points.
Exploratory Pathway Analysis 
Ingenuity Pathway Analysis (IPA) was used to explore biological 
networks enriched by genes identified through the differential 
expression analysis. Follow-up exploratory analyses were 
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conducted to examine differences as a function of treatment type 
and response status.
RESULTS
Clinical Outcome 
Of the 68 subjects, 67.7% responded and 47% remitted with 
treatment with a mean decrease in HamD17 score of 60% (Table 1); 
by treatment group, 60.0% (37.5%) of ESC subjects and 78.6% 
(60.7%) of BUP subjects responded (remitted), respectively. 
There was a trend toward a greater proportion of male patients 
and a greater degree of improvement in the group of patients 
treated with BUP, although these differences were not statistically 
significant between the two treatment conditions. Thirty-six of 
the ESC- and 28 of the BUP-treated subjects completed 8 weeks 
of treatment. The number of subjects who completed treatment 
who had blood drawn for GE studies at each time point is shown 
in Table 1.
Gene Expression Analyses
The comparison of baseline to week 1, 2, and 8 samples revealed 
156, 121, and 585 differentially expressed probes, respectively, at 
an uncorrected threshold of p < 0.005 (Figure 1). We did not 
explore differences between groups treated with ESC versus BUP 
given the small sample sizes when stratifying by treatment. GE 
data therefore were collapsed across treatments to examine the 
effects of treatment on GE irrespective of the specific drug used.
Only a subset of gene transcripts showed a change in expression 
at more than one time point, with 7 shared between the first and 
second weeks, 31 between the first and eighth week, 14 between 
the second and eighth week, and only 4 across first-, second-, and 
eight-week time points. To limit the number of comparisons in 
further data analyses, we restricted our detailed investigations to 
the most robust effect of those transcripts showing differential 
expression: 8 weeks compared to baseline (585 genes).
An examination of GO.BP categories revealed increased 
expression for several process terms, although none of these terms 
were statistically significant at the 0.05 level, after correction for 
multiple comparisons with FDR. The top 10 GO.BP process terms 
are shown in Table 2A. To supplement enrichment analyses of 
GO terms, we also tested for enrichment of gene pathways using 
a compiled set of lists from CHDI. While there was increased 
expression of several of these pathways, none were significantly 
enriched after correction for multiple comparisons (FDR p > 
0.05). The top 10 pathway terms are presented in Table 2B.
To further interrogate these results, we submitted the list of 
585 differentially expressed genes (at uncorrected p < 0.05) for 
annotation enrichment to DAVID (at an uncorrected threshold 
of p < 0.05). Five biological process terms were significantly 
enriched: regulation of cell proliferation, GE, cellular biosynthetic 
process, positive regulation of cell proliferation, and positive 
regulation of biological process. Two molecular function terms 
were significantly enriched, specifically RNA binding and cis–
trans isomerase activity.
Examination of gene sets preferentially enriched for specific 
cell types within the nervous system did not reveal a significant 
overlap between our global treatment effect gene list and genes 
preferentially expressed in any of these cell types.
Examination of the results of nine previous peripheral GE 
studies of patients undergoing antidepressant treatment and 
with published gene lists available for comparison revealed 
a significant overlap of 18 genes (FDR q = 0.046) between 
our global treatment effect gene list and one other published 
gene list (Guilloux et al., 2015) comparing non-remitters to 
remitters at pretreatment baseline. The list of overlapping genes 
is provided in Table 3. There also was not a significant overlap 
with genes expressed in the any region of the thalamus, but there 
was a trend (p < 0.07) toward overlap with genes involved in 
the Wnt/β-catenin pathway in the anterior thalamus (Table 4). 
There were a total of 10 individual genes that were identified in 
the present study and at least two previous studies. This list is 
shown in Table 5.
There was no significant overlap between our gene list and 
previous preclinical studies (above) of drug-specific genomic 
signatures in the mouse brain examining the effects of either 
BUP or fluoxetine.
TABLE 2A | Enrichment of top 10 gene ontology biological process terms in the 
global treatment effect gene set.
Gene Ontology biological process terms (N genes 
overlapping)
FDR corrected 
q-value
Translational termination (14) 0.46
Viral life cycle (21) 0.64
Cellular metabolic process (244) 0.64
Cellular component disassembly (31) 0.64
Cellular protein complex disassembly (16) 0.64
Nuclear-transcribed mRNA catabolic process (13) 0.64
mRNA metabolic process (27) 0.64
Translational elongation (13) 0.64
mRNA catabolic process (13) 0.64
Submandibular salivary gland formation (2) 0.64
TABLE 2B | Enrichment of top 10 gene pathways in the global treatment effect 
gene set.
Gene pathways (N genes overlapping) FDR 
corrected 
q-value
Reactome pathway: influenza viral RNA transcription and 
replication (10)
0.08
Reactome pathway: eukaryotic translation and elongation (9) 0.08
Reactome pathway: influenza life cycle (11) 0.08
Reactome pathway: influenza infection (11) 0.08
Reactome pathway: translation (11) 0.08
Reactome pathway: GTP hydrolysis and joining of the 60S 
ribosomal subunit (9)
0.08
Reactome pathway: peptide chain elongation (8) 0.08
Reactome pathway: eukaryotic translation and termination (8) 0.08
Reactome pathway: viral mRNA translation (8) 0.08
Reactome pathway: SRP-dependent co-translational protein 
targeting to membrane (9)
0.08
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DISCUSSION
The results reported here are consistent with those of previous 
studies and indicate a significant effect of antidepressant 
medication treatment on GE in peripheral blood. We identified 
significant transcriptional changes in genes that were up- or 
down-regulated over the course of 8 weeks of antidepressant 
treatment with either ESC or BUP, two medications in 
widespread clinical use (American Psychiatric Association, 
2010). The number of genes showing differential expression 
increased over the course of treatment, with 585 genes 
showing transcriptional changes by week 8. This emphasizes 
the importance of considering GE not just at end of treatment 
but at a series of time points during antidepressant treatment, 
ranging from the first week through the end of a full course 
of 8 weeks. There was limited overlap in the genes that were 
up- or down-regulated at each time point, suggesting that there 
may be changes in the specific pattern of gene regulation at 
each time point. In contrast to some previous studies, there was 
no relationship between changes in GE and clinical outcomes 
of antidepressant treatment, which may reflect heterogeneity 
among subjects, so that a change in expression in a particular 
subset of genes is sufficient to lead to clinical improvement in 
some individuals but not others.
The purpose of this study was to generate hypotheses and 
to identify genes to examine using bioinformatics tools. By 
comparing GE at weeks 1, 2, and 8 to baseline, we obtained 
156, 121, and 585 significant differences in expression using an 
uncorrected threshold of p < 0.005. We selected this threshold 
to be in line with previous recommendations for preventing 
bias in this type of analysis (Carvalho et al., 2016). However, 
there is no convention for selecting an appropriate statistical 
threshold in genome-wide GE analyses of such samples, because 
the preprocessing and analysis steps tend to vary widely across 
groups. While it is common to use a threshold of p < 0.05 with 
a fold-change greater than 1.5, for example, this is arbitrary. 
Moreover, the use of 0.05 as the threshold in our study would 
likely have identified a very large number of genes and included 
potentially spurious findings. Our use of a threshold of p < 
0.005 was motivated partly by our previous experience with 
similar datasets, and also reasoning that this threshold, while 
more conservative than p < 0.05, would not restrict the lists 
of significant genes to a number too small to allow further 
interrogation with bioinformatics tools.
This dataset is among of the largest of a growing number of 
studies that have examined GE in peripheral blood associated 
with antidepressant treatment (Mamdani et al., 2011; Belzeaux 
et al., 2012; Mamdani et al., 2014; Redei et al., 2014; Guilloux 
et  al., 2015; Hodgson et al., 2016; Belzeaux et al., 2016; 
Jansen et al., 2016; Pettai et al., 2016). In contrast to several of 
these studies, we did not detect a significant association between 
changes in GE and clinical outcome (Mamdani et al., 2011; 
Mamdani et al., 2014; Redei et al., 2014; Belzeaux et al., 2016; 
Hodgson et al., 2016; Pettai et al., 2016) or between exposure 
to different antidepressant medications (Hodgson et al., 2016). 
It is possible that a larger sample size would be needed to 
detect these types of differences in GE. It also is possible that 
the therapeutic effects of antidepressants are not reflected by 
global GE, or that such changes are not reliably or consistently 
reflected in peripheral blood cells (as opposed to nervous 
system tissue). The use of peripheral samples is currently 
standard in the field and ethical and technical factors prevent 
ready access to nervous system cell types, except for cadaveric 
tissue or nasal epithelium (as recently reported for subjects 
with schizophrenia and autism) (Lepagnol-Bestel et al., 2008; 
Dong et al., 2012; Abdolmaleky et al., 2014; Choi et al., 2014; 
Gandal et al., 2018). This approach is less likely to be useful 
for studies of MDD or the response to antidepressants; while 
MDD is a chronic and recurrent condition, the phenotype of 
illness is not always expressed consistently, and response to 
antidepressant frequently is time-limited.
A subset of the 585 genes showing differential expression 
at 8 weeks showed similar changes at week 1 (31) and week 2 
(14) comparisons with baseline (Figure 1). The differences in 
TABLE 3 | Eighteen genes overlapping between treatment-related gene list 
and Guilloux et al., 2015.
Gene symbol
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3
ADAR Adenosine deaminase, RNA-specific
ADIPOR1 Adiponectin receptor 1
EPOR Erythropoietin receptor
FAM136A Family with sequence similarity 136, member A
GSR Glutathione reductase
LSM7 LSM7 homolog, U6 small nuclear RNA and MRNA 
degradation associated
MARCKS Myristoylated alanine-rich protein kinase C substrate
NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 
8kDa
PBX1 Pre-B-cell leukemia homeobox 1
R3HDM4 R3H domain containing 4
RASSF7 Ras association (RalGDS/AF-6) domain family (N-terminal) 
member 7
ROMO1 Reactive oxygen species modulator 1
RPL27 Ribosomal protein L27
RPS10 Ribosomal protein S10
SP2 Sp2 transcription factor
SUGP2 SURP and G-patch domain-containing 2
TMEM208 Transmembrane protein 208
TABLE 4 | Thirteen genes overlapping between treatment-related gene list and 
genes selected by Wisniewska et al. (2012).
Gene symbol
DPYSL5 Dihydropyrimidinase-like 5
FGF10 Fibroblast growth factor 10
GABRG2 Gamma-aminobutyric acid (GABA) A receptor, gamma 2
HOXC6 Homeobox C6
ITGA7 Integrin, alpha 7
KDM2B Lysine (K)-specific demethylase 2B
MARCKS Myristoylated alanine-rich protein kinase C substrate
QRFP Pyroglutamylated RFamide peptide
RAP2B RAP2B, member Of RAS oncogene family
SDPR Serum deprivation response
SMYD2 SET and MYND domain-containing 2
SYT5 Synaptotagmin V
TPM1 Tropomyosin 1 (alpha)
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TABLE 5 | Genes showing differential expression in current study and at least two previous studies.
Gene 
name
Number of 
previous 
studies 
showing 
differential 
expression
Study 1 Study 2 Study 3 Study 4 Gene function
map2k3 2 Belzeaux2012suppletable.txt Pettai et al., 2016 
mmc1.cvs
Signaling pathway (dual specificity kinase)
sp2 3 Belzeaux2012suppletable.txt Belzeaux et al., 2016 
mmc3.csv
Guilloux et al., 
2015
Transcriptional factor (activates mRNA 
synthesis)
atxn10 2 Belzeaux2012suppletable.txt Mamdani et al., 2011
tp201112x1.csv
tp201112x2.csv
Signaling pathway (activates the Ras-MAP 
kinase pathway)
chchd1 2 Belzeaux et al., 2016 mmc3.csv Mamdani et al., 2011
tp201112x1.csv
tp201112x3.csv
Mitochondrial translational factor
serac1 2 Belzeaux et al., 2016 mmc3.csv Mamdani et al., 2011
tp201112x1.csv
tp201112x3.csv
Mitochondrial phospholipid remodeling
c6orf106 2 Belzeaux et al., 2016 mmc3.csv Mamdani et al., 2011
tp201112x1.csv
tp201112x2.csv
Brain function unknown
(expression associated with poor human 
cancer prognosis)
kdm2b 2 Belzeaux et al., 2016 mmc3.csv Wisniewska et al., 
2012 1471-2164-
13-635-S1.xls
Wnt/β-catenin pathway in thalamus
Regulation of histone methylation
smyd2 2 Belzeaux et al., 2016 mmc3.csv Wisniewska et al., 
2012 1471-2164-
13-635-S1.xls
Wnt/β-catenin pathway in thalamus
Regulation of histone methylation
MARCH8 2 Hodgson et al., 2016 Table S1 Mamdani el al., 2011 
2011-12-16203- 
Supplementary_
table4.xls
Ubiquitin protein ligase
MARCKS 4 Mamdani et al., 2011
tp201112x2.csv
Wisniewska et al., 
2012 1471-2164-
13-635-S1.xls
Redei et al., 
2014.pdf
Guilloux 
et al., 2015
Wnt/β-catenin pathway in thalamus
Signaling (most prominent substrate for 
protein kinase C)
FIGURE 1 | Venn diagrams of genes differentially expressed over time, and the intersection of genes between each comparison. Differential expression analyses 
were conducted to compare expression levels within patients and between the indicated timepoints: BL = baseline, TP1 = week 1, TP2 = week 2, TP8 = week 
8 after pharmacotherapy; e.g., TP1vs BL indicates those genes differentially expressed between TP1 as compared to BL. The number of genes differentially 
expressed at a threshold of p < 0.005 between each pair of time points are indicated. Those genes showing a change in expression across multiple comparisons 
are indicated in the intersections of each diagram. In (A), the number of genes showing increased expression is indicated in red, while the number of genes showing 
decreased expression is indicated in green. The total number of differentially expressed genes is shown in (B).
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GE over time suggests that there may be different phases of 
gene regulation over the course of antidepressant treatment, 
with some genes showing only early transcription changes 
and fewer showing consistent change over time. GE studies of 
peripheral blood would be particularly well-suited to detect 
such transient state-dependent changes. It also is possible, 
however, that a number of the changes detected at only one 
or two time points during treatment represent false positive 
changes in GE. Future studies should examine changes in GE 
over time to verify the present finding.
To characterize the nature of genes identified in our resulting 
global-treatment-effect gene list, we used a number of data-
driven tools, which allowed us to test whether there was an overlap 
between our gene list and reference gene list(s) greater than 
expected by chance. Our analyses using GO terms or pathways 
did not show a significant overlap; by contrast, annotation 
enrichment to DAVID revealed an enrichment of terms 
related to several basic biological processes (e.g., GE, cellular 
biosynthetic process) as well as cell proliferation. This finding 
is consistent with the observation that antidepressant drugs can 
affect a variety of different cellular processes (Blier et al., 1998; 
Miller et al., 2009; Sharp, 2012; Duhr et al., 2014; Stokes et al., 
2015; Sun et al., 2015; Björkholm and Monteggia, 2016).
We did not detect an enrichment for any genes that were 
preferentially expressed in nervous system cell types. The lack 
of a detectable signal for genes enriched in neurons may at 
first pass be surprising, because the putative targets of ESC 
and BUP are neuronally expressed monoamine transporters. 
The clinical response to these drugs, however, is unlikely to be 
confined to the particular receptor to which the drugs initially 
bind. Rather, the long-term, therapeutic response is likely to 
involve neurons in pathways that are downstream from the 
initial drug target (Duman et al., 2016). It is also possible 
that the lack of a signal associated with neuronal or glial cell 
types may reflect the limitations of using a non-neuronal cell 
type for our genomic analysis. Peripheral blood cells provide 
a convenient source for human mRNA and are a common 
tissue source from living patients. It is likely that some 
transcriptional pathways are shared between white blood cells 
and neuronal tissue, but it is even more likely that pathways 
would be shared with microglia, as both function as elements 
of the immune system.
We did detect a significant overlap between the genes 
differentially expressed in the present study and one previous 
study (Guilloux et al., 2015). These genes involve a variety of 
cellular processes, most frequently involving gene regulation and 
transcription (Table 3). This finding is consistent with a putative 
role for antidepressant medications in increasing neuroplasticity 
through changes in GE.
We also detected a trend toward an overlap with genes that 
are differentially expressed in the Wnt/β-catenin pathway in 
the anterior thalamus (Table 4). Wnt signaling is increasingly 
recognized as playing an important role in the mature central 
nervous system, and abnormalities in this signaling pathway 
have been implicated in MDD (Voleti and Duman, 2012; 
Zhou et al., 2016; Tayyab et  al., 2018). Nuclear β-catenin 
accumulates in mature neurons throughout the nervous system, 
particularly anterior thalamic cells where it plays a role in 
regulating expression of voltage- and ligand-gated ion channels 
(Wisniewska et al., 2012). Although the precise anatomic site(s) 
of antidepressant activity are not known, the anterior thalamus 
has the highest concentrations of serotonin transporter receptor 
sites in the brain and has been postulated to be a primary site 
of action of SSRI antidepressant medications such as ESC. 
Multiple reports have shown changes in cerebral oscillatory 
activity in prefrontal region during antidepressant treatment 
on a time frame similar to the GE changes reported here (Cook 
et al., 2002; Cook et al., 2005; Bruder et al., 2008; Bares et al., 
2010; Leuchter et al., 2015; Leuchter et al., 2017).
There were 10 genes showing differential expression 
in the current study that showed differential expression 
in at least two previous treatment studies or in the Wnt/β-
catenin pathway (Table 5). Two of these genes are involved 
in cell signaling pathways, four in gene regulation, three in 
the Wnt/β-catenin pathway, and one of unknown function. 
The fact that Wnt/β-catenin pathway genes show expression 
changes in multiple studies is intriguing because changes in 
prefrontal rhythmic oscillatory activity have been reported 
as a reproducible specific biomarker of ESC efficacy. It is 
tempting to speculate that genes regulating excitability such as 
voltage- and ligand-gated ion channels in some brain regions 
might be differentially expressed in patients treated with 
antidepressants. This possibility remains speculative but may 
be relevant to GWAS studies linking loci near several channel 
genes to several psychiatric disorders.
We did not examine GE changes in patients treated with 
ESC versus BUP because our sample size was likely too small 
to reliably detect differences in expression associated with 
particular antidepressants, such as have been reported in 
larger studies of ESC and nortriptyline (Hodgson et al., 2016). 
Our findings of a robust change in GE when collapsing across 
treatments suggest it is possible that the major initial or 
downstream effects of current antidepressants at a molecular 
level are relatively similar, despite variability in the response 
of particular patients to each drug (Rush et al., 2011). Despite 
differences in the immediate effect of antidepressants on 
extracellular amine concentrations, it is possible that the 
downstream therapeutic effects of antidepressants occur via 
common pathways. If so, the molecular signatures of divergent 
antidepressants could be quite similar regardless of which 
molecules they bind to initiate these events.
These results must be interpreted within the context of several 
limitations of this study. First, while this is among the larger studies 
of GE during antidepressant treatment, the sample size of 64 
subjects limits the statistical power to detect differential expression 
as well as association with treatment efficacy. Second, the unusual 
design of the study in which treatment was changed from ESC to 
BUP in some subjects restricts our ability to attribute changes in 
expression to any particular antidepressant treatment. Nevertheless, 
the consistency in GE changes over time and the overlap with one 
relevant previous study suggests that there may be a shared signal 
underlying treatment response that is detectable in peripheral 
blood across studies. Further studies of drug-induced GE will help 
us to triangulate on loci that are relevant to depression. The power 
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afforded by integrating results across additional datasets may help 
overcome the limited sample sizes in most extant studies. It is 
possible that reliable detection of significant changes will require 
peripheral blood samples from thousands of patients during 
treatment. If so, very large-scale efforts or alternative methods may 
be needed to address these questions.
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